董事会认为，2024年建议股份购回及林医生的意向均显示董事会及林医生对股份的内含价值及集团在2024年的业务前景充满信心。Simcere Pharmaceutical Group (03309) announced that the board of directors has been closely monitoring the recent stock price of the company, as well as considering the 202...
China Fortune Financial News App news, Simcere Pharmaceutical Group (03309) announced that the board of directors has been closely monitoring the recent stock price of the company, and has the intention to repurchase shares based on the proposed share buyback in 2024. After considering the company's financial performance and business prospects, as well as the financial performance announced in the company's financial performance report for the six months ended June 30, 2024, the board of directors announced that they have decided that the company will use up to HK$0.1 billion in cash to buy back shares on the market from the date of this announcement for a period of 12 months.
The executive director and controlling shareholder of the company, Dr. Lin Shun Chao (Dr. Lin), has also informed the board of directors that he (and/or entities controlled by him) may seek suitable opportunities to increase its shareholding in the company, and any such shareholding will be strictly conducted in accordance with applicable regulatory requirements for securities trading.
The board of directors believes that the proposed share buyback in 2024 and Dr. Lin's intentions both demonstrate the board of directors' and Dr. Lin's confidence in the intrinsic value of the shares and the group's business prospects in 2024.
